Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616625 · ClinicalTrials.gov registry record
Cardiovascular Effects of Prenatal Methamphetamine Exposure
A clinical trial, sponsored by University of California, Davis.
- Completed
- Registry status
- 26
- Enrollment target
NCT04616625 is a clinical trial that has completed, run by University of California, Davis. The registered enrollment target is 26 participants.
The verdict
NCT04616625 has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease, structural and electrical remodeling of cardiac tissue leading to arrhythmias and heart failure, and pulmonary hypertension.1 In addition, MA can cause neurotoxicity with harmful effects on neurodevelopment in the children who had prenatal exposure.5-8 Currently neonatal providers do not perform detailed cardiovascular evaluation in newborn period or long term neurodevelopmental assessments as outpatient for the newly born infants with prenatal exposure to MA, and they do not qualify for early intervention. The goal of the investigators is to perform detailed cardiovascular evaluation in neonatal period and estimate baseline prevalences and follow up with developmental and cardiovascular assessment using a questionnaire at 12 months in a cohort of neonates enriched with those who had prenatal exposure to MA.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-10-05 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616625
The ClinicalTrials.gov registry entry for NCT04616625 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04616625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04616625 about?
NCT04616625 is a clinical study titled "Cardiovascular Effects of Prenatal Methamphetamine Exposure". Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease, structural and electrical remodeling of cardiac tissue leading to arrhythmias and heart failure, and pulmonary hypertension...
What is the current status of trial NCT04616625?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2020-10-05. Estimated completion is 2023-06-30.
Who is sponsoring clinical trial NCT04616625?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.